PRNCR1 and prostate carcinoma: Recently, two lncRNAs, PCGEM1 and PRNCR1, have been suggested in prostate cancer to act as mediators of castration-resistance disease by binding, in a direct and sequential fashion, to the androgen receptor (AR), causing ligand-independent activation of its gene expression programs [1].